sC5b-9 Antibody (Monoclonal - neoantigen) , Biotinylated

A biotin conjugated murine monoclonal antibody to a neoantigen on the terminal complement complex.

250 µL

Purified human protein.

IgG2bk

≥ 95% by SDS PAGE

This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.

Short term (30 days) 4˚C. Long term at or below –20˚C.

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC.